HDAC-IN-88

• Description :

  HDAC-IN-88 (Compound HJ-9) is the inhibitor for HDAC that inhibits HDAC6, HDAC1, HDAC2, HDAC8 and HDAC3 with IC50s of 0.226, 1.103, 2.308, 3.255 and 3.864 μM, respectively. HDAC-IN-88 inhibits the proliferation of cancer cell HepG2, HCT116 and MV4-11 with IC50 of 5.47, 9.78 and 0.38 μM, inhibits the migration of HCT116, arrests the cell cycle at G0/G1 phase, and induces apoptosis and autophagy in MV4-11. HDAC-IN-88 reduces ROS level and mitochondrial membrane potential. HDAC-IN-88 exhibits antimalarial activity that inhibits P. falciparum 3D7 with EC50 of 165 nM. HDAC-IN-88 also exhibits anti-angiogenic activity[1].

• UNSPSC :

  12352211

• Target :

  Apoptosis; Autophagy; HDAC; Mitochondrial Metabolism; Parasite; Reactive Oxygen Species (ROS)

• Related Pathways :

  Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Field of Research :

  Cancer; Infection

• Smiles :

  O=C(NO)CCCCC1=CN(N=N1)[C@@H]2C([H])[C@]3([H])CC[C@@H](C)[C@@]4([H])[C@]35[C@](C[C@](C)(OO5)CC4)([H])C2

• Molecular Formula :

  C23H36N4O4

• Molecular Weight :

  432.56

• References & Citations :

  [1]He J, et al., Design, synthesis, and biological evaluation of novel artemisinin-based HDAC inhibitors with antitumor and antimalarial activities. Bioorg Chem. 2025 Apr;157:108312.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC2; HDAC3; HDAC6; HDAC8